VEGF Inhibitor Drugs Market
VEGF Inhibitor Drugs Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
VEGF Inhibitor Drugs Market Size and Growth
The VEGF inhibitor drugs market is experiencing significant growth, driven by increasing cancer incidence and advancements in targeted therapies. The market size is projected to reach USD 8.9 billion by 2025, with a CAGR of 3.7%. Competitive landscape and regulatory changes further influence market dynamics and drug development strategies.
Companies Covered
(Covid 19 Impact Covered)
◍ Pfizer
◍ Novartis AG
◍ GlaxoSmithKline plc
◍ Sanofi
◍ AstraZeneca plc
◍ Bristol-Myers-Squibb Company
◍ Genentech, Inc. (Roche)
◍ Merck & Co., Inc.
◍ Bayer AG
◍ Eli Lilly & Company
The VEGF inhibitor drugs market is competitive, with key players like Pfizer, Novartis, and Roche driving growth through innovative therapies for cancer and eye diseases. These companies enhance market expansion via research, strategic partnerships, and new formulations.
- Pfizer: $51.3 billion (2022 revenue)
- Novartis: $52.5 billion (2022 revenue)
- Roche: $68.7 billion (2022 revenue)
Request Sample Report
Market Segmentation
By Application
Oncology
Ophthalmology
Others
Request Sample Report
By Product
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Market Growth
Request Sample Report
$ 2.86 Billion
